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Abstract 
Selenium (Se) supplements are commonly prescribed to autoimmune thyroiditis (AIT) patients by European endocrinologists, despite 
the lack of official guidelines. The majority of Europe is depleted of natural Se sources, and the daily population intake does not comply 
with recommended values. Optimal individual plasma Se concentration is reached when the selenoproteins (selenoprotein P, glutathione 
peroxidase) are fully saturated. However, Se intake has to be regulated because both Se shortage and overdose negatively impact health. In 
the case of AIT, Se may alleviate symptoms or prevent progression to hypothyroidism and postpartum hypothyroidism. Se supplementa-
tion in euthyroid, subclinical, or overt hypothyroid AIT patients decreased thyroid autoantibodies, lowered or maintained the TSH level, 
decreased the fT4/fT3 ratio, reduced the body’s oxidative stress and inflammatory status, and amended quality of life and thyroid ultra-
sound structure and volume. In pregnant females, adequate Se intake protected them against miscarriages, preeclampsia/hypertension, 
preterm birth, small-for-gestational-age infants’ birth, and improved child’s neuropsychological development. In the elderly population, 
adequate Se supplementation decreased cardiovascular diseases and hypertension risk, but prolonged intake of excessive doses increased 
the all-cause mortality rate. Routine Se supplementation implementation requires from researchers and clinicians consideration of spe-
cific populational differences in natural Se and iodine supply, the patient’s clinical situation (supplementation simultaneously or before 
levothyroxine treatment, AIT/non-AIT hypothyroidism), individual response to supplementation (Se and selenoprotein P assessment), 
predisposition (genetic testing), the status of other trace elements, and the interplay between those micronutrients. Moreover, the safety 
of commercially available Se formulations, doses, and duration of treatment should be determined. Proper guidelines are warranted to 
standardise the medical approach to Se supplementation. This article presents a comprehensive review of recent randomised-controlled 
trials, meta-analyses, and clinical trials concerning the risks and benefits of Se supplementation in different clinical settings and specific 
populations with particular emphasis on AIT in a practical manner. (Endokrynol Pol 2021; 72 (2): 153–162)
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Introduction 
The influence of diet supplements on autoimmune 
thyroid disease (AIT) has been debated recently. Grow-
ing patients’ interest in nutraceutical products as an al-
ternative form of AIT treatment, wide availability and 
uncontrolled intake of supplements (over-the-counter 
in most countries) forces scientists and clinicians 
to expand and update the evidence-based state of 
knowledge. Although no positive recommendation 
for selenium (Se) supplementation in AIT has been 
provided by European or American Endocrine/Thyroid 
Societies, it is widely supported worldwide in daily 
clinical practice. According to an Associazione Medici 
Endocrinologi (AME) Survey completed by 815 doctors 
(91.6% endocrinologists) in 2016, the majority of doctors 
(79.4%) prescribe Se to euthyroid AIT patients, aiming 
for hypothyroidism delay or a decrease of thyroid an-
tibodies (TA) titre. Interestingly, only 20% of doctors 
would advocate against Se if a patient requests any 
form of treatment instead of observation. In patients 
with subclinical hypothyroidism (SHT) and positive TA, 
two-thirds of respondents would prescribe Se, whereas 
only one third — with negative TA, regardless of ad-
ditional levothyroxine (LT4) treatment. In euthyroid 
AIT women who are pregnant or conceiving, 40% of 
doctors decided on Se supplementation, intending to 
prevent postpartum thyroiditis (PPT). The preferable 
dose in all groups was 100–200 μg/day [1]. Surprising 
results of the previous survey encouraged investiga-
tors to expand the questionnaire within the European 
Thyroid Association (ETA) members (147 physicians, 
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- a value required to achieve optimal glutathione 
peroxidase (GPx) expression and in practice used to 
plan an adequate diet for healthy people, and 2. Up-
per limit (UL) — above which side effects were noted. 
In the case of Se, the recommended RDA-UL values 
from birth to 6 months of age is 15–45 μg/day (from 
breast milk), 6 months to13 years of age ranging from 
20-45 to 40–280/day, and from 14 years until adulthood 
— 55–400 μg/day. The RDA is temporarily higher in 
pregnancy (60 μg/day) and during lactation (70 μg/day) 
due to increased foetus and newborn requirements [7]. 
Similarly, the European Food Safety Authority (EFSA) 
recommended a higher (70 μg/day) adequate Se in-
take for adults (including pregnancy) and in lactating 
women (85 μg/day) [8]. The value for adults (55 μg) is 
in accordance with the Scientific Committee for Food 
(SCF) of the European Commission, but the UL was set 
at a lower value of 300 μg/day. However, the Reference 
Nutrient Intake (RNI) for Se in the UK is 60 μg/day in 
women and 75 μg/day in men and lactating women 
[9]. Nevertheless, most European countries have a Se 
daily intake lower than preferable (30–90 μg/day) [10]. 
As a result, some countries are Se-repleted, including 
North America, Venezuela, Greenland, Japan, and cer-
tain parts of China, whilst others are Se-depleted — the 
majority of countries in Europe, the Middle East, and 
certain parts of China [4]. Most European countries, 
except parts of Norway and Finland, have insufficient 
natural Se supplies, with the lowest values recorded 
in Eastern Europe. For example, Polish students have 
a deficient Se intake, with daily dose average around 
25 μg/day according to one study [11]. In the last 
decades, progressively lower Se concentrations have 
been reported in Polish women, regardless of their 
pregnancy status, probably due to decreased food Se 
intake. Moreover, in Polish pregnant females, Se serum 
status was lower than the European average (31% had 
Se level < 50 μg/L vs. 4.5% in other European countries) 
[12]. A multicentre comparison between Italy, Greece, 
Romania, and Austria showed suboptimal Se levels in 
each cohort, with the highest serum Se concentrations 
in Italy [13]. Se status has also declined in the UK in the 
last decades, which coincides with the bread-making 
industry switching from high-Se wheat imported from 
North America to low-Se wheat grown in Europe or the 
UK, using fertilizers rich in S instead of Se, decreasing 
use of coal (Se-rich rock) as a fuel, and an increasing 
preference of a vegetarian diet over meat consump-
tion [3]. An interesting example is northern Germany, 
where the division of countries with moderate Se in 
the west and those with low Se in the east follows the 
instated West-East German border. Such differences 
may be explained by the use of fertilisers with differ-
ent Se content. The national program of implementing 
84% endocrinologists). Sixty-six per cent of them 
would use Se in AIT; however, only 20% recognised 
convincing evidence favouring Se supplementation. In 
the LT4-treated AIT group, 50% of responders would 
prescribe Se, where 71% would not recommend it in 
pregnancy. In AIT subjects not receiving LT4 physicians 
were more likely to support Se supplementation (69%), 
and a lower rate (67%) would not prescribe it in case of 
pregnancy. Besides the goals mentioned above, some 
respondents consider the quality of life (QoL) and thy-
roid ultrasound (US) image improvement as expected 
supplementation outcomes. The preferable treatment 
pattern was ≤ 200 μg/day of selenomethionine (SeMet) 
for weeks to months [2]. 
This article provides a comprehensive review of 
the potential role and usefulness of Se supplementa-
tion in various clinical settings based on recent ran-
domised-controlled trials (RCTs), meta-analyses, and 
clinical trials and systemises knowledge concerning the 
role of Se in human health among different populations, 
with particular emphasis on AIT, in a practical aspect. 
Natural sources and populations’ supplies 
of Se
Populations’ replenishment of Se is country-specific and 
largely depends on soil content and bioavailability to 
enter the food chain through plants. The vast majority 
of the Earth’s rocks have a low Se content, but some 
sedimentary and volcanic rocks are enriched with 
this trace element, explaining the geographical differ-
ences [3]. The majority of Se in our body is obtained 
from consuming seafood (e.g. tuna, halibut, sardines, 
shrimps), animal organs and meat (e.g. ham, beefsteak, 
turkey, beef liver, chicken), cereals, grains and crops 
(e.g. pasta, brown rice, whole-wheat bread), milk or 
dairy products (e.g. cottage cheese, milk, eggs), and 
fruit/vegetables (e.g. spinach, bananas) [4]. However, 
the food with the highest Se content is Brazil nuts [5]. 
Importantly, its concentration in nuts is notably diver-
sified depending on the place of origin and brand; it 
is non-standardized (no product information about Se 
concentration or geographic region of import) and vari-
able (high seed to seed and batch variation). Analysis 
of 13 commercially available Brazil nut brands, only 
from Brazil, showed that the batch from the largest 
nut producer in the Se-rich Amazonas state exceeded 
by up to 3.5 times the tolerable upper intake level (UL) 
for Se in a standard serving of 6–8 nuts. Therefore, the 
authors opted to reduce the recommended portion of 
any Brazil nuts to 3 nuts, to avoid Se overdosing [6]. 
The National Institutes of Health (NIH) in the 
U.S. established 2 terms with regards to nutrient con-
sumption: 1. recommended dietary allowance (RDA) 
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sodium selenate-rich fertilisers in primarily Se-depleted 
Finland in the early 1980s resulted in improvement of 
Se intake in the Finnish population from 30 mg/d to 
100 mg/d in the late 1980s and promoted Finland to the 
list of European countries with adequate Se intake [14]. 
Se status assessment
Assessment of blood Se concentration may be mis-
leading due to unspecified substitutions of SeMet for 
methionine in many proteins, where it is functionally 
inactive. Functional and individual Se status assess-
ment may be evaluated using 2 markers, the activity of 
which is related to Se body supply: GPx concentration 
in whole blood, plasma, erythrocytes or thrombocytes 
and Selenoprotein P (SePP) in plasma/serum, where 
the latter is more accurate due to the crucial role in 
tissue Se distribution and higher required plasma Se 
concentration (100–120 μg/L) than for GPx (90 μg/L) to 
be fully expressed. Therefore, the optimal plasma/serum 
Se concentration of 120–125 μg/L reflects the maximal 
selenoprotein activity and sufficient Se storage. The 
positive correlation between blood Se and SePP exists in 
subjects until adequate Se concentration fully saturates 
the selenoprotein. However, both serum biomarkers 
are not tissue-specific and do not reflect the thyroid Se 
concentration [8, 15, 16]. Of note, there are no proposed 
region-specific reference ranges for plasma Se, which 
would be especially beneficial in the context of thyroid 
diseases, and no reliable thyroid biomarkers for Se 
status assessment are currently available.
Se optimal supply and health 
According to Rayman et al., only Se-deficient individu-
als are reasonable candidates for substitution of this 
micronutrient due to the proposed U-shaped relation-
ship between Se and health effects, where neither Se 
deficiency nor Se overdosing are beneficial [17]. 
Except for AIT, selenopenia is associated with 
increased risk for Keshan and Kashin-Beck disease, 
colorectal cancer in females and prostate cancer in 
males, infertility/reproduction complications, mental 
decline, more flawed immune defence, increased viral 
virulence, and higher mortality. Conversely, excessive 
Se intake produces selenosis (nail and hair loss, garlic 
breath odour, tachycardia, gastrointestinal and neu-
rological symptoms), dermatitis, non-melanoma skin 
cancer, and increased prostate cancer risk and mortality. 
According to some studies, prolonged Se supplementa-
tion may also facilitate diabetes mellitus type 2 (DM2) 
development [18,19]. Nevertheless, the latest meta-anal-
ysis from 3 RCTs (SELECT, NPC, and Selenium Trial) 
analysing 20,290 participants with 200 μg Se daily intake 
for 3–7.7 years, showed only a nonsignificant increase in 
DM2 occurrence between the study and placebo group 
(OR = 1.18, 95% CI: 0.95–1.4). However, observational 
studies have linked high Se status with increased DM2 
incidence (OR = 2.03, 95% CI: 1.51–2.72) [20]. Of note, 
the tendency was observed only in the highest Se con-
centration quartiles, in which sufficient Se supply was 
exceeded, and it mainly focussed on males [21]. On the 
other hand, DM2 or insulin resistance may trigger the 
liver to overproduce SePP, which alters per se plasma 
Se concentration. To explain whether high Se is a cause 
or effect of impaired glucose metabolism, convincing 
large RCTs and meta-analyses are needed [22]. Some 
authors associate Se deficiency with development of 
metabolic syndrome, obesity, and DM2 as a first-line 
consequence [21]. 
Se in diet supplements
The bioavailability, bioactivity, and potential toxicity of 
Se in the diet largely depend on the type of food and 
chemical properties of associated micronutrients. Se 
is present in the diet primarily in the organic form of 
selenocysteine (SeCys) and SeMet, which is most likely 
absorbed via transcellular diffusion in the small intes-
tine [23]. On the other hand, the inorganic form of Se, 
selenite or selenate, is present in food to a lesser degree. 
SeMet is a form of Se that is most readily absorbed. At 
the same time, SeCys, selenate, and selenite are less 
bioavailable [24]. Supplementation of Se is frequently 
achieved using SeMet or Se yeast (60% of which is 
SeMet) [25]. If supplementation is recommended to 
a patient, preference should be given to the organic 
form, SeMet, rather than inorganic. An attractive thera-
peutic option may be the patented Danish product by 
Pharma Nord (SelenoPrecise®), used in large RCT (UK, 
Danish, Swedish PRECISE), which contains organic Se 
yeasts (100 μg of Se per tablet, stable Se content: 66% of 
SeMet and < 1% of inorganic forms) with high bioavail-
ability of 88.7%, proven by the EFSA [26]. 
Se supplementation in euthyroid AIT 
patients
The idea of Se supplementation in thyroid diseases 
(mainly AIT) arose from epidemiological studies, in 
which Se-depleted regions had a higher number of AIT 
patients. A Chinese study of 3038 people from Se-rich 
and 3114 subjects from low-Se provinces proved in-
creased prevalence and higher odds ratio (OR) for AIT 
(OR = 0.47, 95% CI: 0.35–0.65), SHT (OR = 0.68, 95% 
CI: 0.58–0.93), overt hypothyroidism (OR = 0.75, 95% 
CI: 0.63–0.90), and goitre (OR = 0.75, 95% CI: 0.59–0.97) 
in the latter group ; altogether 18 vs. 30.5% (p < 0.001) 
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intervention in the first group. The authors concluded 
that Se alleviates the thyroid autoimmune process by 
improving body antioxidative status [31]. Se supple-
mentation (60 and 180 μg/day) significantly reduced 
proinflammatory cytokine release mediated by INF-g 
(CXCL-9 and 10) in AIT euthyroid females who were 
not treated with LT4 in comparison to the placebo 
group. This serves as evidence for a Se-positive immu-
nomodulatory effect and may prove advantageous in 
cases of an undetected change in thyroid parameters 
[32]. An Italian group (2016) found fT3 increases at 3 
and 6 months and an fT4 decrease 3 months after Se 
supplementation in patients at the time of AIT diag-
nosis without LT4 treatment. The results of peripheral 
hormones were explained by the enhanced iodothy-
ronine deiodinase activity due to incorporation of Se, 
which led to the augmented conversion of fT4 to fT3 
[33]. Although Se supplementation resulted in a 9.9% 
a-TPO decrease after 6 months in AIT patients in one 
study, its discontinuation led to an a-TPO level rise of 
4.8% at 12 months. In contrast, the continuation of Se 
supplementation reduced a-TPO further by up to 21% 
at the above-mentioned time point. Interestingly, the 
observed a-TPO level in the group who continued the 
treatment at the end of the study was more reduced 
among non-smokers [34]. Nevertheless, no effect on 
a-TPO and TSH was seen in a well-designed, ran-
domised, placebo-controlled, and double-blind study 
from an iodine-sufficient region, after 200 μg/day 
sodium selenite for 6 months given to Se-deficient 
(not fully expressed SePP) euthyroid AIT females 
without LT4 treatment. The possible explanation may 
be that iodine-sufficient subjects are less sensitive to 
immunosuppressive Se properties [35]. Interindividual 
variations in response to Se supplementation among 
AIT patients may be explained by genetic variation. 
Genotyping revealed that single nucleotide polymor-
phism in r25191g/a of SePP gene (SEPP1) is expressed 
in Se responders, which may be associated with a more 
prominent a-TPO decline [36]. 
Se supplementation in hypothyroid AIT 
patients
The results of the “SETI” study were published in 2020. 
The research included patients with SHT, in whom 
TSH was within the range 4.26–10.00 mIU/L, due to 
AIT (positive a-TPO), with no history of LT4 treatment. 
After 4 months of treatment with 83 μg/day of SeMet, 
48.9% of participants (responders) re-established 
euthyroidism (TSH ≤ 4.2); the rest (non-responders) 
remained hypothyroid (TSH > 4.2). At the end of 
the study, Se levels in serum significantly increased, 
while fT4 concentrations significantly decreased in 
[27]. In addition, in a comparator multi-centre study 
from 4 European low Se-equipped countries, the Se 
concentrations were significantly lower in AIT patients 
than in patients with non-AIT thyroid diseases [13]. 
The obtained results suggest that Se supplementation 
might reduce the incidence of thyroid diseases. The 
majority of studies concerning Se supplementation 
were performed on euthyroid AIT patients. The com-
monly measured primary outcome in those studies 
was a decrease in TA. However, some authors under-
lined the need to find clinical evidence, expressed 
by thyrotropin (TSH) decrease (or no progression 
to overt disease) or lowering LT4 dose in the course 
of combined LT4 and Se treatment. US echogenicity, 
oxidative and inflammatory body status, or QoL are 
frequently considered as secondary outcomes. As-
sessment of TA (the higher the level, the better the 
response), individual Se level at baseline (substitution 
or supplementation), geographical area of living, and 
iodine status (iodine deficiency exacerbates the effects 
of Se deficiency) should be taken into account in the 
interpretation of results. In the latest published me-
ta-analysis (2017) concerning data from European and 
Brazilian patients, the authors failed to find the disease 
progression (expressed by TSH rise) in LT4-untreated 
subjects after 3, 6, or 12 months of Se supplementation 
[28]. Another meta-analysis (2016) by the same authors 
revealed that levels of anti-thyroid peroxidase antibod-
ies (a-TPO) and anti-thyroglobulin antibodies (a-TG) 
declined significantly after 3 months in the group of 
patients who did not receive LT4. In the LT4-treated 
group a-TPO decreased at 3, 6, and 12 months, while 
a-TG decreased only after 12 months, which is in ac-
cordance with the previous meta-analysis results. Se 
supplementation favourably impacted the mood and 
general well-being of participants in this study [29, 
30]. The countries that were analysed in these stud-
ies had a baseline plasma Se concentration below the 
normal range and reached a Se serum concentration 
of 70–85 μg/L and 37 μg/L upon conclusion of the 
European and Brazilian studies, respectively. Both 
meta-analyses underline no justification for routine 
Se supplementation in AIT euthyroid patients, due to 
lack of clinical evidence for improvement of the disease 
course. The adequately Se supplied AIT population 
without LT4 treatment (basal serum Se 110 ± 16 μg/L 
in the study group and 123 ± 19 in healthy controls) 
had significantly decreased a-TPO, but not a-TG and 
TSH, after 3 months of 200 μg/day Se treatment in 
comparison to healthy controls. Additionally, the 
oxidative marker panel (total antioxidant capacity, 
superoxide dismutase, malondialdehyde) indicated 
an oxidative stress pattern in AIT patients compared to 
healthy controls. This improved significantly after Se 
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both groups versus baseline. Six months after Se 
withdrawal, the TSH level was controlled again; in 
the non-responder group 14.2% of patients achieved 
euthyroidism, while in the responder group this was 
up to 83.3%. The authors indicated that 4 months of 
Se supplementation allows for normalisation of TSH 
levels. Thus, Se is a promising therapeutic option for 
patients with SHT [37]. The aforementioned observa-
tion is pursuant with a previous study (2016), which 
was conducted on a group of patients with mild SHT 
due to AIT. The time of treatment and the dose of 
SeMet were the same. At the end of the study, 17.2% of 
participants were again euthyroid. Follow-up studies 
conducted 5 months later showed that euthyroidism 
was maintained mainly in the Se group [38]. These 
studies included patients with no history of thyroid 
hormone therapy, but Se treatment may also be use-
ful as an adjunct to LT4 for patients with AIT and 
SHT. SeMet supplementation with 200 μg/daily with 
LT4 for 6 months caused a significant reduction in 
a-TPO concentration: 46% after 3 months and 55.5% 
after 6 months. The group receiving only LT4 had 
a decrease of a-TPO of 21% after 3 months and 27% 
after 6 months. There were no significant changes 
in a-TG and thyroid hormone levels. The reduction 
of a-TPO levels might be the result of the influence 
of Se on the immune system and oxidative stress 
[39]. Se supplementation with LT4 is also effective 
in reducing the a-TPO level in AIT hypothyroid pa-
tients. Three months of treatment with 200 μg sodium 
selenite/day + LT4 resulted in a significant reduction in 
a-TPO and a-TG levels [40]. Se added to LT4 in euthy-
roid and hypothyroid AIT patients decreased a-TPO 
and a-TG more than in patients treated exclusively 
with LT4. Moreover, euthyroid AIT patients were less 
Se deficient at baseline than hypothyroid ones, and 
the latter subgroup reached lower TA levels after Se 
treatment. These results showed that Se supplementa-
tion in addition to LT4 may be beneficial in the later 
disease stage. Additionally, Se intake significantly 
ameliorated levels of proinflammatory cytokine (IL-2) 
and therefore corrected disturbed immune balance in 
AIT patients, which was not observed in the group 
without Se supplementation [41]. However, another 
study showed that SeMet supplementation (200 
μg/day) had no significant effect on the a-TPO level; 
however, this resulted in a substantial reduction in 
a-TG after 3 months of treatment [42]. The reason for 
the different responses to Se supplementation remains 
unclear. However, the duration of the treatment and 
the dose of Se preparations may affect the results. It 
is also possible that the initial concentration of TA, Se 
level, and thyroid disease duration play a crucial role 
in the outcome.
Se supplementation in AIT and healthy 
pregnant women
Se supplementation in pregnancy is currently not 
supported by the American Thyroid Association (ATA) 
due to conflicting results of studies, omitted impact of 
baseline Se and iodine status, and potential DM2 risk 
[43]. European Thyroid Association (ETA) guidelines do 
not raise the issue of Se supplementation for the man-
agement of subclinical hypothyroidism in pregnancy 
and children. Nevertheless, the majority of studies 
justify its potential advantages. Considering the physi-
ological Se decline throughout pregnancy (partially 
due to haemodilution), the risk of developing severe 
Se deficiency is higher in this group [44]. In healthy 
pregnant females from Poland, Se concentrations physi-
ologically decreased by 24% from the first trimester to 
the end of pregnancy [12]. However, Se deficits in AIT 
pregnant females were not more intensified than in 
healthy pregnant controls from a Se-depleted, mildly 
iodine-deficient area [45]. The question of whether 
low Se status has a negative impact on the course of 
AIT in pregnancy remains unanswered. In pregnant 
women, similarly to the general population, Se supple-
mentation reduces the TA titre. Taking into account the 
narrow therapeutic index of Se, interventional studies 
on pregnant females are frequently characterized by 
lower Se proposed doses in comparison to the rest of 
the studied populations. The “SERENA” study (2019) 
demonstrated a significant reduction of a-TPO in the 
third trimester of pregnancy and 6 months after de-
livery in euthyroid females with AIT taking 83 μg of 
SeMet since their first trimester. Although an a-TPO 
decrease during pregnancy is a natural immunosup-
pressive body reaction, preventing rejection of the 
foetus, TA tends to rise dramatically after delivery, as 
observed in the placebo group. The above-mentioned 
results provide evidence that Se supplementation 
during pregnancy reduces the risk of postpartum 
thyroiditis (PPT) [46]. This is in accordance with the 
previous finding, where 200 μg of SeMet given to AIT 
women (with or without LT4) from the 10th gestation 
week until the postpartum period significantly reduced 
the incidence of PPT (28.6% vs. 48.6% for placebo) and 
persistent hypothyroidism (11.7% vs. 20.3%). Addition-
ally, the researchers observed an improvement in US 
echogenicity of thyroid parenchyma in the Se-treated 
group [47]. However, in euthyroid AIT patients with 
no additional LT4 treatment recruited for “SPRINT” 
(double-blind, randomized, placebo-controlled study), 
in which the group of 114 women from a mild-to-mod-
erate iodine-deficient country received a lower dose 
of Se (60 μg/day) from the 12th week of pregnancy, no 
reduction in a-TPO (baseline lower median levels than 
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in the previous study) was observed (54.2 vs. 65.6% in 
placebo). Nevertheless, Se modulated thyroid func-
tion by increasing fT4 (p < 0.029) and decreasing TSH 
(p < 0.050) throughout the pregnancy more in the Se 
group than in the placebo group. This may be explained 
by the additive Se immunomodulatory effect on the AIT 
course [48]. An interesting interventional clinical trial 
on the influence of immunomodulatory factors (includ-
ing low Se dose) on intracytoplasmic sperm injection 
(ICSI) effectiveness in infertile AIT euthyroid patients 
was registered in 2019; however, the results have not 
been published yet [49]. 
Moreover, Se intake may also contribute to an un-
complicated pregnancy course. Within the “SPRINT” 
group, Se supplementation in Se-depleted subjects 
resulted in reduction of OR for developing pregnan-
cy-induced hypertension or preeclampsia [50]. Women 
with the lowest Se serum concentration in the 10th-14th 
gestation week (from quartile Q1) were 3 times more 
prone to deliver small-for-gestational-age (SGA) new-
borns (OR = 3.02, p = 0.019) than in other quartiles [51]. 
Maternal Se-rich food intake was shown to decrease the 
risk of preterm birth [52]. In the population of women 
with spontaneous abortions, Se levels were significantly 
lower than in controls, potentially due to the associated 
risk of increased placental oxidative stress and tropho-
blast damage in early pregnancy [53]. 
Encouraging evidence originates from infertility 
studies of men and women, in which Se supplementa-
tion of < 200 μg/day positively impacted sperm motil-
ity and enhanced oocyte cycle evolution, possibly by 
reducing oxidative stress [54]. 
Future double-blind placebo-controlled studies 
raising the issue of Se supplementation in pregnancy 
are warranted, especially in high-risk pregnancies in 
women from Se-depleted regions. Concomitant assess-
ment of SePP as a marker of individual response for 
adjusting correct Se doses and the mutual interplay be-
tween different micronutrients may be relevant [55, 56].
The impact of Se on quality of life
Few clinical trials have assessed the effect of Se 
supplementation on QoL. According to these studies, 
Se supplementation (as sodium selenite or SeMet 200 
μg/day for 3-6 months) resulted in improved well-being 
and mood and diminished fatigue in a group of patients 
with AIT, compared to controls [39, 57, 58]. More insight 
is expected from the “CATALYST” study, which is sched-
uled to be completed in December 2021. The aim of the 
study is to assess whether 200 μg/day Se supplementa-
tion for 12 months alongside LT4 will have an impact 
on QoL in AIT patients [59]. 
The impact of Se on the US image
Se influence on thyroid US remains questionable. 
Supplementation of 50 μg SeMet per day for 3 months 
among children with AIT led to thyroid volume regres-
sion by over 30% [60]. In a study of a large group of 
patients (1100 women; 792 men), an inverse associa-
tion between Se level and thyroid volume was shown 
(p = 0.003). In a group of tested women, an increase in 
serum Se concentration by 1 μmol/L caused a decrease 
in the thyroid gland volume by 0.18 mL. Moreover, low 
Se status was significantly related to goitre risk (OR 
0.07, 95% CI: 0.008–0.6) and thyroid hypoechogenicity 
(OR = 0.2, 95% CI: 0.06–0.7), but not to thyroid nod-
ules. In the male group, there was no relationship be-
tween Se level and thyroid structure or thyroid volume 
[61]. Another study showed that low Se concentration 
increases the risk of developing multiple nodules in the 
thyroid gland (p = 0.087) [62]. A Se dose of 200 μg/day 
with LT4 for 3 months in AIT patients improved thyroid 
US echogenicity [58]. On the other hand, in studies 
where Se was supplemented in a dose of 80 μg, 160 
μg, or 200 μg for 3–12 months there was no change in 
echogenicity and volume of the thyroid gland at the 
end [32, 63]. Further research is essential to find the 
optimal dose and time required for Se to exert its ben-
eficial effects. It is necessary to investigate patterns of 
thyroid US in patients’ who would benefit most from 
the supplementation. 
Se supplementation in non-AIT 
hypothyroidism
Dietary Se deficiency may cause hypothyroidism, 
which was identified in 3 cases of children with SHT and 
no signs of infection. The thyroid US picture was unaf-
fected. The plasma Se concentrations in subjects were 40 
μg/L, 32 μg/L, and 43 μg/L. Each child received 10 μg/kg 
daily of sodium selenite. After 4 weeks, clinical symp-
toms improved, and thyroid gland parameters and Se 
levels became normal. The authors concluded that the 
direct cause of hypothyroidism was Se deficiency and 
reduced activity of type II 5’-deiodinase, which confirms 
the vital role of Se in the aetiology of hypothyroidism, 
even without concomitant AIT [64]. With that said, 
high-quality evidence is needed to confirm the above 
observation. This effect may be applicable to hypo-
thyroidism coexisting with other end-stage chronic 
diseases, in which fT4 to fT3 conversion is impaired 
— for instance, in renal failure [65]. Determination of 
hypothyroid aetiology (AIT vs. non-AIT) and distin-
guishing these 2 subgroups would be advantageous 
in future clinical trials. 
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Se supplementation in a paediatric 
population
A Se deficit in childhood is a considerable risk factor 
for poor physical and cognitive development [66]. Se 
plays an important role in synaptogenesis, myelination, 
and neuronal cell differentiation by regulating thyroid 
hormones [67]. Maternal erythrocyte Se (Ery-Se) con-
centrations were associated with neonatal development 
measures at 1.5 years [68]. An increase in maternal Se by 
0.50 μg/g haemoglobin was associated with improved 
language comprehension by 3.7 points (0.5 SD, 95% 
CI: 0.40–7.1, p = 0.028) and increased psychomotor 
development by 12 points in girls (0.9 SD, 95% CI: 
4.3–19, p = 0.002) at 1.5 years of age. In a follow-up 
study, a positive association was also observed between 
maternal Ery-Se in early pregnancy and the outcomes 
in children at 10 years [69]. An increase of maternal 
Ery-Se from 5th to 95th percentile was associated with 
a full developmental score by approximately 8.1 points 
(95% CI: 3.8–13). Similarly, a Polish study reported 
a significant positive association between Se levels in 
blood collected during the first trimester of pregnancy 
and motor skill development at 1–2 years of age and 
cognitive development at 2 years of age, and border-
line association (β = 0.2, p = 0.05) was observed for 
language development at 2 years of age [44]. A similar 
association between maternal urinary Se (23 ± 8.6 
μg/L) and cognition at 4 years of age was also reported 
in Greece (n = 575) [70]. Conversely, a recent study 
from Spain suggests an inversion of this relationship 
between maternal Se concentration and neuropsy-
chological development at 1 year of age when the Se 
concentration in the first trimester exceeds 86 μg/L 
[71]. However, a study conducted in the U.S. did not 
identify an association between high levels of Ery-Se 
in pregnant women (206 μg/L, n = 872) and children’s 
cognitive function at 7.7 years of age [72]. Assessment 
of preschool children in Ethiopia revealed that low 
serum Se was associated with lower cognitive scores as 
validated tests [66]. Another body of research focuses 
on the effects of Se nutritional intake in children with 
autism spectrum disorder (ASD). A recent literature 
review of 4 studies found significant differences in Se 
tracing in the hair of children with ASD, compared to 
unaffected children [73]. Two of these 4 studies found 
increased Se levels in the hair of children with ASD, and 
the other 2 studies reported the opposite finding. With 
that said, more studies will be needed to evaluate the 
significance of Se and ASD association and its clinical 
implication. Additionally, Se deficiency was associated 
with the development of Keshan disease in children 
between the ages of 2 and 7 years and women of re-
productive age. The possible aetiology may be related 
to mutation promoting in a poor Se environment in the 
genetic material of Coxsackie B virus’s genetic mate-
rial, resulting in its increased virulence and extensive 
myocardial damage leading to dilated cardiomyopathy 
[74]. An Se shortage in neonates and children is a risk 
factor for decreased motor and cognitive function. 
However, children’s cognitive outcome is also affected 
by other factors associated, among others, with poor 
care, inadequate cognitive stimulation, and parasitic 
infections [75, 76].
Se supplementation in adults  
and the elderly population
Fluctuations in Se serum concentration are believed 
to intensify chronic inflammation, increase monocyte 
migration into the endothelium, and promote mono-
cyte transformation into macrophages and eventually 
foam cells, thus advancing the development of ath-
erosclerosis and increasing the risk of cardiovascular 
diseases (CVD) [77]. A recent meta-analysis reported 
a 50% increase in Se concentration to be associated with 
24% reduction in the risk of developing ischaemic heart 
disease [78]. A similar conclusion was drawn by a study 
that reported a reduced risk of CVD (RR: 0.66, 95% CI: 
0.40–1.09) and mortality (RR: 0.69, 95% CI: 0.57–0.84) 
in individuals with high Se status [79]. Also, UK and 
Denmark PRECISE randomised, double-blinded, 
placebo-controlled, clinical trials explored the effects 
of Se supplementation on total cholesterol (T-C) and 
non-HDL cholesterol [80, 81]. In the UK PRECISE clini-
cal study (n = 501), healthy participants (60 to 74 years 
old) were supplemented with 100, 200, or 300 μg/day 
Se-enriched yeast tablets or placebo for 6 months [80]. 
Compared to placebo, Se supplementation of 100 and 
200 μg/day significantly decreased T-C and non-HDL 
cholesterol in the plasma. Supplementation with 300 
μg/day for 6 months significantly increased HDL-cho-
lesterol but did not affect either total or non-HDL 
cholesterol. Conversely, a similar study carried out in 
a Danish population found no significant difference in 
total or HDL cholesterol concentrations between pla-
cebo and Se supplementation groups after 6 months or 
5 years, despite similarities in Se baseline concentrations 
in the 2 populations (88.6 μg/L in Denmark, 91.2 μg/L 
in the UK) [81]. Se homeostasis is also implicated in the 
maintenance of blood pressure. A recent observational 
study conducted in a group of 2169 Inuit described 
a potential blood pressure-lowering effect seen with 
an Se-rich diet [82]. Participants with low Se and high 
mercury serum levels were more likely to develop CVD, 
including hypertension (OR = 1.76), stroke (OR = 1.57), 
and heart attack (OR = 1.26). In contrast, other stud-
ies described a positive association between high Se 
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serum concentration and hypertension [83, 84]. Based 
on the given research, the cardiovascular benefits of 
Se supplementation are unclear and should not be 
recommended. Both Se deficiency and excess have 
been associated with increased mortality. According 
to U.S. Third National Health and Nutrition Examina-
tion survey analysis (n = 13887), mortality exhibited 
a U-shaped association with the lowest mortality rate 
at a serum Se concentration of 135 μg/L and high mor-
tality with either lower or higher Se concentration [4, 
85]. In the Danish PRECISE clinical trial, mortality was 
assessed 10 years after 5-year supplementation with 
100, 200, or 300 μg Se/day as Se-enriched yeast or pla-
cebo yeast [86]. Supplementation with 300 μg Se/day 
resulted in an 11.3% (95% CI: 0.0–22.6%) increase in 
all-cause mortality compared to placebo 10 years after 
treatment. Conversely, a prospective study found an in-
verse relationship between Se intake and all-cause CVD 
mortality in men and women. However, no significant 
difference in mortality was observed between Se intake 
and cancer-related mortality in both sexes [87]. 
Conclusions
According to our literature review, the recommenda-
tion of Se supplementation is supported by everyday 
clinical practice. However, Se supplement seems to be 
uncontrollably prescribed (no baseline and follow-up 
Se assessment) and not adjusted to the specific popula-
tion’s profile (children, adults, males, females, pregnant, 
non-pregnant, AIT, non-AIT thyroid disease, and area 
of living). According to the authors’ best knowledge, 
no commercially available oral Se preparation has been 
approved by the U.S. Food and Drug Administration. 
Thus, available Se formulations and effective doses 
need to be revised and standardised. The reference 
ranges for Se concentrations in various geographical 
areas are lacking, and there is a need to determine 
thyroid tissue-specific biomarkers for Se functional 
assessment. Clinical trials have explored many health 
benefits of Se supplementation; however, its narrow 
therapeutic index, patients’ geographical location, indi-
vidual Se intake, and specific clinical setting should be 
considered to evaluate the benefit-risk balance before 
Se supplementation. Future studies comparing regions 
with varying natural supplies of Se and iodine and in-
vestigating the effects of the interplay of these elements 
on the course of AIT would be valuable. Among suc-
cessful Se supplementation candidates may be pregnant 
females, especially those from iodine- and Se-depleted 
areas, with risk factors like AIT. Se implementation 
in this population may prevent the development of 
selenopenia, PPT, hypertension, and poor neonatal 
outcomes. However, clear recommendations on indi-
cations for treatment, therapy duration, and suitable 
doses need to be established. Factors determining the 
response to Se should be elucidated, taking into consid-
eration genetic predisposition and mutual interrelations 
with other trace elements.
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